Evidence map›Paper›PMID 42074127›Full record

ArticleInternational journal of molecular sciences2026

Cross-Disease Breathomics by PTR-TOF-MS: Multiclass Machine Learning and Network Remodeling Across Asthma, COPD, Cystic Fibrosis, and Lymphangioleiomyomatosis.

Malika Mustafina, Artemiy Silantyev, Aleksandr Suvorov, Stanislav Krasovskiy, Marina Makarova, Alexander Chernyak, Olga Suvorova, Anna Shmidt, Daria Gognieva, Aleksandra Bykova and 7 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Malika MustafinaDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0002-0250-9949
Artemiy SilantyevWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.
Aleksandr SuvorovWorld-Class Research Center "Digital Biodesign and Personalized Healthcare", I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0002-2224-0019
Stanislav KrasovskiyPulmonology Research Institute under the Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia.
Marina MakarovaPulmonology Research Institute under the Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia.ORCID 0000-0003-4913-087X
Alexander ChernyakPulmonology Research Institute under the Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia.ORCID 0000-0002-2001-5504
Olga SuvorovaPulmonology Department, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0001-9661-7213
Anna ShmidtPulmonology Department, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0002-1314-0091
Daria GognievaDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.
Aleksandra BykovaDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0002-2035-2340
Nana GogiberidzeDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0003-0243-6724
Andrei AkselrodDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0009-0001-1946-6965
Andrey BelevskiyFederal State Autonomous Educational Institution of Higher Education, N.I. Pirogov Russian National Research Medical University, 1 Ostrovityanova str., Bldg. 6, 117513 Moscow, Russia.
Sergey AvdeevPulmonology Research Institute under the Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia.
Vladimir BetelinResearch Institute for Systemic Analysis of the Russian Academy of Sciences, 117218 Moscow, Russia.
Abram SyrkinDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.ORCID 0000-0002-6452-1222
Philipp KopylovDepartment of Cardiology, Functional and Ultrasound Diagnostics, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia.

Funding

Artemiy Silantyev the government assignment 1023022600020-6, "Application of mass spectrometry and exhaled air emission spectrometry for cardiovascular risk stratification."Philipp Kopylov the Russian Science Foundation (RSF) grant No. 24-15-00549, "Development of methods for non-invasive diagnosis of chronic lung diseases using proton mass spectrometry of exhaled air and artificial intelligence methods
6 · The paper itself

Abstract

Chronic obstructive and inflammatory lung diseases share overlapping clinical manifestations and spirometric features, complicating differential diagnosis and monitoring. In this study, we performed an integrative real-time proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF-MS) breathomics analysis to assess whether exhaled volatile organic compound (VOC) profiles enable multiclass discrimination among bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and lymphangioleiomyomatosis (LAM), with healthy individuals as controls. Breath VOC data from 843 subjects were analyzed using a stratified 70/30 train/test split. An ensemble feature selection strategy based on gradient boosting (XGBoost with SMOTE within cross-validation) identified stable VOC panels (top 25% selection probability), yielding 29 VOCs and 31 features including clinical covariates. On the independent test set, the VOC-only model achieved a macro-averaged one-vs-one (OvO) AUC of 0.866 (95% CI 0.829-0.903), while the combined model improved to 0.888 (95% CI 0.853-0.919), indicating modest value of clinical variables. Pairwise analysis demonstrated highest discrimination for CF (AUC up to 0.988), whereas BA and LAM showed lower sensitivity (<0.60), likely reflecting heterogeneity and limited sample size. Given differences in age, sex, BMI, and smoking status across cohorts, confounding effects were assessed, confirming that VOC signatures retain independent diagnostic information. Disease-specific VOC interaction networks revealed distinct remodeling patterns, with central metabolites not captured by univariate analysis. Overall, PTR-TOF-MS breathomics demonstrates proof-of-concept multiclass discrimination across chronic lung diseases.

Indexed as

AsthmaCystic FibrosisLymphangioleiomyomatosisMachine LearningPulmonary Disease, Chronic ObstructiveVolatile Organic CompoundsAdultBreath TestsFemaleHumansMaleMass SpectrometryMiddle AgedVolatile Organic Compoundsbreathomicsbronchial asthmaCOPDcystic fibrosislymphangioleiomyomatosismachine learningnetwork analysisPTR-TOF-MSVOCXGBoost

Identifiers

PMID42074127
PMCPMC13116732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.